1. Introduction {#Sec1}
===============

Dapagliflozin, a once-daily oral antidiabetic, is a selective inhibitor of the sodium glucose co-transporter type 2 (SGLT2), in development with Bristol-Myers Squibb and AstraZeneca for the treatment of type 2 diabetes mellitus. SGLT2 is a low affinity, high-capacity transporter located in the brush-border membrane of the early segment of the proximal tubule of the kidney. The transporter is responsible for 90% of the glucose reabsorbed by the kidneys. SGLT2 inhibitors maintain blood glucose levels by regulating the reabsorption of filtered glucose. Dapagliflozin is in phase III development in the US, Canada, Europe, Latin America, India and South East Asia, and in phase II development in Japan.

1.1. Company Agreements {#Sec2}
-----------------------

In January 2007, Bristol-Myers Squibb and AstraZeneca entered into a worldwide collaboration agreement to develop and commercialize dapagliflozin, and any additional SGLT2 or DPP IV compounds to arise from the collaboration. Under the terms of the agreement, AstraZeneca paid Bristol-Myers Squibb an upfront payment of \$US100 million, and will also make additional milestone payments of up to \$US650 million for the two compounds, and possible sales milestones up to \$US300 million per product. Both companies will jointly develop the clinical and marketing strategy of the compounds. AstraZeneca also agreed to fund the majority of development costs from 2007 through 2009. Bristol-Myers Squibb will manufacture both compounds and book sales. The agreement initially excluded all activities in Japan. However, the agreement was expanded in December 2008 to include development and commercialization of dapagliflozin in Japan.\[[@CR1],[@CR2]\]

1.2. Key Development Milestones {#Sec3}
-------------------------------

Dapagliflozin is undergoing phase III development for the treatment of type 2 diabetes mellitus at multiple centers worldwide and is in phase II clinical studies in Japan.\[[@CR1]\] Regulatory submissions in the EU and the US are expected in the second half of 2010.

Bristol-Myers Squibb has completed a phase III trial (NCT00643851) that evaluated the safety and efficacy of dapagliflozin in combination with extended-release metformin as an initial therapy compared with dapagliflozin or metformin alone in approximately 600 patients with type 2 diabetes. This randomized, double-blind, active controlled, parallel-group study enrolled patients in the US, Latin America, Philippines, South Korea and the EU. Another phase III study (NCT00528372) is assessing the safety and efficacy of dapagliflozin monotherapy in treatment-naive patients with type 2 diabetes who are not well controlled with diet and exercise, or who have been on medication for at least 24 weeks following diagnosis of type 2 diabetes. The study has completed recruitment of approximately 560 patients in the US, Canada, Latin America (Mexico) and Europe (Russia). Bristol-Myers Squibb is also conducting a phase III study (NCT00528879) of dapagliflozin in 546 patients with type 2 diabetes in combination with metformin in patients uncontrolled by metformin alone. Study centers in the US, Canada and Latin America have completed recruitment and interim results were reported in October 2009.\[[@CR3]\]

Bristol-Myers Squibb and AstraZeneca are conducting a phase III study (NCT01031680) to assess the safety and efficacy of dapagliflozin in patients with type 2 diabetes, cardiovascular disease and hypertension. The study aims to enroll 940 patients in the US, Argentina, Canada, Germany, Romania, Slovakia, Spain, Taiwan, Turkey and Vietnam. Subjects will be randomized to receive dapagliflozin or placebo for 24 weeks plus a 28-week extension period.

A phase II/III, multicenter, randomized, double-blind, placebo-controlled, parallel group study (NCT00663260) is determining the safety, pharmacokinetics and pharmacodynamics of dapagliflozin in approximately 252 patients with type 2 diabetes and moderate renal impairment. The study is being conducted in the US, Australia, Canada, Israel, India, the EU, Latin America, and Singapore and has completed recruitment. In March 2008, the company completed a randomized, double-blind, placebo-controlled, pilot, phase II/III trial (NCT00357370) in 71 patients with type 2 diabetes inadequately controlled by insulin and one or two oral antidiabetics (metformin and/or pioglitazone or rosiglitazone). The study was conducted in the US and Canada. Results of this trial were reported in June 2009.\[[@CR4]\]

Bristol-Myers Squibb completed a randomized, double-blind, parallel, phase IIb trial of dapagliflozin (NCT00263276) in approximately 389 patients with type 2 diabetes in Canada, Mexico, Puerto Rico and the US. The study evaluated the safety and efficacy of dapagliflozin in treatment-naive patients who had inadequate glycemic control on diet and exercise. Results have been reported.\[[@CR5]\] In September 2005, the company completed a phase IIa study (NCT00162305) evaluating the safety, pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 2 diabetes.
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![History](40268_2012_10010047_Tab2){#Tab2}

In March 2010, Bristol-Myers Squibb and AstraZeneca completed enrollment of 16 healthy volunteers in a randomized, crossover, phase I trial (NCT01072578) to assess the effect of dapagliflozin on percent inhibition of glucose re-absorption when dosed once daily (10 mg once daily) versus twice daily (5 mg twice daily). The trial is underway in Germany.

A completed phase I trial (NCT00538174) in approximately 36 Japanese patients evaluated the safety, pharmacokinetics and pharmacodynamics of dapagliflozin administered for 14 days. Additionally, Bristol-Myers Squibb completed a phase I pharmacokinetic drug interaction study (NCT00562250) of dapagliflozin and glimepiride in approximately 11 healthy volunteers in Argentina.

A phase I trial (NCT00726505), which was to characterize the kinetics of renal glucose reabsorption in response to dapagliflozin, in healthy subjects and patients with type 2 diabetes mellitus in the US, was terminated. The reason of termination was not disclosed.

1.3 Patent Information {#Sec4}
----------------------

The US Patent and Trademark Office has issued a patent covering the composition of matter which will expire in 2020.

2. Scientific Summary {#Sec5}
=====================

2.1 Pharmacokinetics {#Sec6}
--------------------

***Phase I:*** In a multiple-dose escalation (2.5--100 mg) trial in 40 healthy volunteers, dapagliflozin exposure (area under the concentration-time curve \[AUC\]) increased dose proportionally. An accumulation index of approximately 1.25 was observed with repeat daily dosing. The mean daily amount of glucose eliminated in the urine was similar after the first dose and after 14 days. Cumulative 24-hour urine glucose excretion after 2.5 and 10 mg dapagliflozin was approximately 50% and 70% of that excreted after doses ≥20 mg, respectively.\[[@CR6]\]

In a single-dose escalation (2.5--500 mg) trial in 64 healthy volunteers, the maximum concentration (C~max~) increased slightly less after an overnight fast compared with that after a high-fat breakfast. In the fasted state, the AUC from time zero to infinity (AUC~inf~) increased slightly more than proportionally with the dapagliflozin dose. After a high-fat breakfast, the median time to C~max~ (t~max~) was delayed by 2.5 hours, geometric mean C~max~ was 39% lower, and AUC~inf~ was 7% lower.\[[@CR7]\]

2.2 Adverse Events {#Sec7}
------------------

***Phase III:*** Dapagliflozin, as adjunctive therapy to metformin, was generally well tolerated in a 24-week, randomized, phase III trial in patients with type 2 diabetes who were inadequately controlled with metformin alone. The rates of adverse events overall were 89%, 95% and 98% in patients who received dapagliflozin 2.5, 5 or 10 mg, respectively, compared with 88% in those who received placebo. Specifically, the incidence of urinary tract infections was not significantly different between the dapagliflozin 2.5, 5 and 10 mg groups and the placebo group (4.4%, 7.3% and 8.1% vs 8.0%, respectively). Rates of genital infections were higher in the dapagliflozin 2.5, 5 and 10 mg arms than the placebo arm (8.0%, 13.1% and 8.9% vs 5.1%, respectively), but these events were mild or moderate in severity and did not result in treatment discontinuation. Dapagliflozin was not associated with any clinically significant electrolyte level increases or changes in renal function. Dapagliflozin decreased blood pressure (BP) to a greater extent than placebo (systolic BP −3.1 to −5.9 vs −0.3 mmHg and diastolic BP −2.1 to −2.7 vs −0.4 mmHg); although there were no cases of hypotension. Hypoglycemic events occurred with a similar frequency in the dapagliflozin 2.5, 5 and 10 mg and groups (2.2%, 3.6% and 3.7% vs 2.9% of patients, respectively), but did not lead to study withdrawal.\[[@CR3]\]

***Phase II/III:*** Adverse events were reported at similar rates across the dapagliflozin treatment arms and the placebo group, in a 12-week trial in 71 patients with type 2 diabetes. Patients were randomized to dapagliflozin 10 mg, dapagliflozin 20 mg or placebo, in addition to insulin and one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone). The numbers of patients experiencing ≥1 adverse event for dapagliflozin 10 mg, dapagliflozin 20 mg and placebo, were 18/24, 16/24 and 15/23, respectively. The most commonly reported (≥5% overall) adverse events for dapagliflozin 10 mg, 20 mg and placebo were: urinary frequency, back pain, nasopharyngitis, nausea, headache and upper respiratory tract infection. One urinary tract infection and five genital tract infections occurred in the dapagliflozin 20 mg group, and one genital tract infection occurred in the placebo group. The number of reported hypoglycemic events was seven for dapagliflozin 10 mg, six for dapagliflozin 20 mg and three for placebo. There was no occurrence of major hypoglycemia.\[[@CR4],[@CR8]\]

![Forecasts](40268_2012_10010047_Tab3){#Tab3}

***Phase II:*** The tolerability of dapagliflozin was examined in a 12-week, phase IIb trial in 389 treatment-naive patients with type 2 diabetes. Patients were randomized to receive either 2.5, 5, 10, 20 or 50 mg of dapagliflozin, metformin 750 mg (titrated up to 1500 mg) or placebo, once daily. The most common adverse events in dapagliflozin recipients were urinary tract infection, nausea, dizziness, headache, fatigue, back pain and nasopharyngitis. Hypoglycemia was reported at a frequency similar to that for metformin, but there were no documented glucose levels of ≤50 mg/dL. There were no clinically meaningful changes in serum sodium, potassium, calcium or creatine, or urinary calcium noted. Serum uric acid declined by 1.0 mg/dL with all dapagliflozin doses tested.\[[@CR9]\]

A phase IIa study showed no serious adverse events or treatment discontinuations due to adverse events following treatment with dapagliflozin and metformin in patients with type 2 diabetes. This 14-day, randomized study involved 47 patients who received dapagliflozin 5, 25, 100 mg or placebo, once daily. Metformin therapy was continued in patients who were receiving already receiving treatment upon entry into the study. Adverse events occurred with similar frequency in subjects receiving dapagliflozin or placebo. The most frequently reported adverse events were constipation, nausea and diarrhea.\[[@CR10]\]

Polyuria and pollakiuria were reported by 1.4% of subjects in the dapagliflozin groups (2.5, 5, 10, 20 and 50 mg), in a phase II study including 389 treatment-naive patients with type 2 diabetes. There were no reports of nocturia.\[[@CR5]\]

***Phase I:*** Dapagliflozin up to 150 mg did not prolong the corrected QT (QTc) interval in 50 healthy male volunteers.\[[@CR11]\]

In a multiple dose escalation (2.5--100 mg) trial in 40 healthy volunteers, 24 adverse events occurred in 16 subjects, 36.7% in the dapagliflozin group and 50% in the placebo group. All events were mild to moderate in intensity and the most common was rash, which occurred in five subjects. Dapagliflozin had no apparent effect on renal safety markers or the QTc interval.\[[@CR6]\]

In a single-dose escalation trial (2.5--500 mg) in 64 healthy volunteers, 22 adverse events occurred in 14 subjects, 21% in the dapagliflozin group and 25% in the placebo group. These were mild to moderate in intensity. A total of 38 subjects experienced 49 laboratory abnormalities, including 11 hematological, seven blood chemistry variations and 31 cases of elevated urinary glucose.\[[@CR7]\]

2.3 Pharmacodynamics {#Sec8}
--------------------

### 2.3.1 Diabetes Mellitus {#Sec9}

***Phase I:*** In a multiple-dose escalation (2.5--100 mg) trial in 40 healthy volunteers, there were no apparent differences between dapagliflozin and placebo in urinary excretion of magnesium, amino acids, calcium, chloride, oxalate, potassium, phosphate, sodium, uric acid, NAG and β2-MG.\[[@CR6]\]

***Preclinical:*** Dapagliflozin reduced the loss of pancreatic function in the high fat fed female ZDF rats with established hyperglycemia. The compound reduced further progression of hyperglycemia and reduced the requirement for insulin to control blood glucose thus preserving beta cell function.\[[@CR12]\]

Similarly, in a model of rapid beta cell loss in male ZDF rats, dapagliflozin 1 mg/kg once daily for 5 weeks prevented the development of diabetes, did not increase bodyweight and preserved beta cell function in a rodent model of type 2 diabetes.\[[@CR13]\]

Data from the study evaluating the effect of dapagliflozin on pancreatic islet morphology in obese female ZDF rats showed that after once daily dose of 1 mg/kg for up to 34 days, the beta cell mass in the lean, obese vehicle and dapagliflozin obese groups were 0.68%, 1.15% and 1.49% of total cell count, respectively. Dapagliflozin also markedly improved islet morphology assessment by 2.3-fold (p \< 0.05) compared with obese vehicle control group. The insulin staining intensity of islets after dapagliflozin was elevated 2.2-fold (p \< 0.05) compared with obese vehicle-treated animals to the extent that there were no detectable differences between dapagliflozin and lean animal control groups.\[[@CR14]\]

In diabetic rats, dapagliflozin acutely induced renal glucose excretion at doses ranging from 0.01 to 1.0 mg/kg of bodyweight without inducing hypoglycemia. Additionally, as early as 2 hours after a single oral dose, there was a significant reduction in plasma glucose levels in diabetic rats treated with dapagliflozin, at doses of 0.1 and 1.0 mg/kg, compared with untreated diabetic rats.\[[@CR10]\]

Treatment with dapagliflozin for 25 days reduced bodyweight in non-diabetic, diet induced obese rats. Significant weight loss was observed with all doses (0.5--5 mg/kg), which was a function of reduced adiposity. Dapagliflozin increased urine glucose concentration, total urine glucose and urine volume. There was also an observed increase in water and food consumption.\[[@CR15]\]

In db/db mice and high fat diet-induced obese (DIO) mice, acute and chronic treatment with dapagliflozin resulted in complete normalization of ambient and fasted glucose levels, without causing hypoglycemia. Chronic treatment with dapagliflozin increased insulin content in islets. Acute and chronic treatment of normoglycemic DIO mice did not significantly affect glucose levels, in contrast to db/db mice. Furthermore, the total bodyweight did not change in dapagliflozin-treated DIO mice despite a significant increase in food and water intake.\[[@CR16]\]

2.4 Therapeutic Trials {#Sec10}
----------------------

### 2.4.1 Diabetes {#Sec11}

***Phase III:*** A phase III randomized trial (NCT00528879) met its primary endpoint of significant reductions in glycosylated hemoglobin (HbA~1c~) levels with 24 weeks of treatment with dapagliflozin in addition to metformin, compared with placebo and metformin, in patients with type 2 diabetes mellitus who were inadequately controlled with metformin alone (n = 546). Patients received either dapagliflozin 2.5, 5, 10 or placebo, in addition to metformin at a dosage of at least 1500 mg/day. At 24 weeks, the mean changes from baseline in HbA~1c~ levels were significantly greater in the dapagliflozin 2.5, 5 and 10 mg groups (−0.67%, −0.70% and −0.84%, respectively) than in the placebo group (−0.30%). Mean reductions in fasting plasma glucose (FPG) were also significantly greater in the dapagliflozin groups (−17.8, −21.5 and −23.5 mg/dL, respectively) than in the placebo group (−6.0 mg/dL). The proportion of patients who achieved an HbA~1c~ level of \<7% at 24 weeks was significantly greater in the dapagliflozin 5 and 10 mg arms, compared with the placebo arm (37.5% and 40.6% vs 25.9%), but the difference between dapagliflozin 2.5 mg and placebo was not significant for this endpoint. Significantly greater decreases in bodyweight were observed in all three dapagliflozin groups, compared with the placebo group.\[[@CR3],[@CR17]\]

Sustained increases in urinary glucose excretion were observed in dapagliflozin-treated patients with type 2 diabetes enrolled in a phase III trial (n = 389). A higher proportion of patients in each of the dapagliflozin groups experienced a 5% reduction in bodyweight compared with placebo. There were small dose-related increases in 24-hour urine volume observed in the dapagliflozin groups (from 107 to 470 mL in the 2.5 and 50 mg/day groups) compared with reduction of 112 and 96 mL in the placebo and metformin groups, respectively. Dapagliflozin had no apparent effect on appetite, as assessed using a visual analogue scale.\[[@CR18]\]

Dapagliflozin, at doses of 2.5, 5, 10, 20 and 50 mg/day, improved glycemic control in treatment-naive patients with type 2 diabetes enrolled in a phase III trial (n = 389). All doses of dapagliflozin were associated with significantly greater reductions in the proportion of HbA~1c~ than placebo at 12 weeks; the four highest doses also resulted in significantly greater reductions than placebo in fasting plasma glucose, and postprandial glucose measures reduced to a greater extent with dapagliflozin than placebo.\[[@CR19]\]

***Phase II/III:*** Results from a 12-week, double-blind trial demonstrated that dapagliflozin produced greater improvements across all key glycemic measures studied, in patients with type 2 diabetes who were treated with high doses of insulin and commonly used oral anti-diabetes medications (OADs), compared with placebo (placebo plus OADs plus insulin). The trial enrolled 71 patients who were inadequately controlled by insulin and one or two baseline OADs (metformin and/or pioglitazone or rosiglitazone). Patients were randomized to dapagliflozin 10 mg, dapagliflozin 20 mg or placebo, given once daily. At 12 weeks, the adjusted mean decreases in HbA~1c~ from baseline were 0.61% in the dapagliflozin 10 mg group and 0.69% in the dapagliflozin 20 mg group, compared with an increase of 0.09% for placebo. The percentage of patients that achieved HbA~1c~ of \<7% at 12 weeks was 13% for dapagliflozin 10 mg and 4.3% for dapagliflozin 20 mg, compared with 5.3% for placebo. The percentage of patients that achieved HbA~1c~ decrease from baseline of ≥0.5% was 65.2% for both the dapagliflozin groups, compared with 15.8% for placebo. The change from baseline in fasting plasma glucose at 12 weeks was +2.4 mg/dL for dapagliflozin 10 mg and −9.6 mg/dL for dapagliflozin 20 mg, compared with +17.8 mg/dL for placebo. Decreases in bodyweight were 4.51 kg, 4.3 kg and 1.88 kg in the dapagliflozin 10 mg, 20 mg and placebo groups, respectively.\[[@CR4],[@CR8]\]

***Phase II:*** The efficacy of dapagliflozin was examined in a 12-week, phase IIb trial in 389 treatment-naive patients in type 2 diabetes. Patients were assigned to receive either 2.5, 5, 10, 20 or 50 mg of dapagliflozin, metformin 750 mg (titrated up to 1500 mg) or placebo, once daily. All doses of dapagliflozin were associated with significantly (p \< 0.01) greater reductions in HbA~1c~ than placebo. The change from baseline in HbA~1c~ was −0.71%,−0.90%, −0.18% and −0.73% in recipients of dapagliflozin 2.5 and 50 mg, placebo and metformin, respectively. The four highest doses of dapagliflozin were also associated with significantly (p \< 0.01) greater reductions in FPG than placebo. The change from baseline in FPG was −19.3, −30.5, −5.8 and −18.0 mg/dL in recipients of dapagliflozin 5 mg and 50 mg, placebo and metformin, respectively. Postprandial glucose (PPG) measures were also reduced to a greater extent with dapagliflozin than with placebo. Dapagliflozin also increased mean glucosuria values over 12 weeks, to 51.8--85.0 g/day, while metformin and placebo values were 5.6 and 5.7 g/day, respectively. Mean percent bodyweight reductions were 2.7--3.4%, 1.7% and 1.2%, and reductions in body mass index values were 0.9--1.1, 0.5 and 0.3 for the dapagliflozin, metformin and placebo arms, respectively. Small dose-related mean 24-hour urine volume increases were seen at week 12 in the dapagliflozin groups, and dapagliflozin did not appear to affect appetite. Statistical comparisons were not applied to the metformin arm.\[[@CR5],[@CR9]\]

A phase IIa study showed positive results with dapagliflozin in the treatment of patients with type 2 diabetes. Dapagliflozin 5, 25 and 100 mg doses were all associated with significant reductions in fasting serum glucose on day 13, compared with baseline (reductions of 14.5%, 17.3% and 21.9%, respectively). Additionally, placebo was associated with a 6.3% reduction in fasting serum glucose, over this time. This 14-day, randomized study involved 47 patients with type 2 diabetes who received dapagliflozin 5, 25, 100 mg, or placebo, once-daily; metformin therapy was continued in patients who were already receiving treatment upon entry into the study.\[[@CR10]\]
